Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Nelson Leung, S Vincent Rajkumar
Light chain cast nephropathy (LCCN) is a leading cause of acute kidney injury (AKI) in patients with multiple myeloma (MM) and is now defined as a myeloma defining event. While the long-term prognosis has improved with novel agents, short-term mortality remains significantly higher in patients with LCCN especially if the renal failure is not reversed. Recovery of renal function requires a rapid and significant reduction of the involved serum free light chain. Therefore, proper treatment of these patients is of the utmost importance...
March 29, 2023: Blood Cancer Journal
#2
JOURNAL ARTICLE
Fen Saj, Yadav Nisha, Prasanth Ganesan, Smita Kayal, Rakhee Kar, Dhanapathi Halanaik, Biswajit Dubashi
Bortezomib, lenalidomide, and dexamethasone induction chemotherapy (VRd), followed by autologous stem cell transplantation (ASCT), are the standard of care for patients with newly diagnosed multiple myeloma (NDMM). Pomalidomide is currently approved for relapsed-refractory multiple myeloma. This single-arm, open-label, phase 2 study was the prospective evaluation of the efficacy and safety of bortezomib, pomalidomide, and dexamethasone (VPd) induction for NDMM. We used Fleming's two-stage design for sample size calculation...
March 24, 2023: Blood Cancer Journal
#3
LETTER
Jiahua Niu, Huiying Qiu, Fang Xiang, Lin Zhu, Jun Yang, Chongmei Huang, Kun Zhou, Yin Tong, Yu Cai, Baoxia Dong, Yuan Lu, Xuedong Sun, Liping Wan, Xueying Ding, Haopeng Wang, Xianmin Song
No abstract text is available yet for this article.
March 24, 2023: Blood Cancer Journal
#4
LETTER
Marietheres Evers, Martin Schreder, Thorsten Stühmer, Franziska Jundt, Regina Ebert, Tanja Nicole Hartmann, Michael Altenbuchinger, Martina Rudelius, Martin Kuric, Wyonna Darleen Rindt, Torsten Steinbrunn, Christian Langer, Sofia Catalina Heredia-Guerrero, Hermann Einsele, Ralf Christian Bargou, Andreas Rosenwald, Ellen Leich
No abstract text is available yet for this article.
March 23, 2023: Blood Cancer Journal
#5
JOURNAL ARTICLE
Konstantin Golovine, Gleb Abalakov, Zhaorui Lian, Srinivas Chatla, Adam Karami, Kumaraswamy Naidu Chitrala, Jozef Madzo, Margaret Nieborowska-Skorska, Jian Huang, Tomasz Skorski
Deletion of ABL1 was detected in a cohort of hematologic malignancies carrying AML1-ETO and NUP98 fusion proteins. Abl1-/- murine hematopoietic cells transduced with AML1-ETO and NUP98-PMX1 gained proliferation advantage when compared to Abl1 + /+ counterparts. Conversely, overexpression and pharmacological stimulation of ABL1 kinase resulted in reduced proliferation. To pinpoint mechanisms facilitating the transformation of ABL1-deficient cells, Abl1 was knocked down in 32Dcl3-Abl1ko cells by CRISPR/Cas9 followed by the challenge of growth factor withdrawal...
March 23, 2023: Blood Cancer Journal
#6
REVIEW
Noopur Raje, María-Victoria Mateos, Shinsuke Iida, Donna Reece
Almost all patients with multiple myeloma (MM) will eventually develop disease that has relapsed with or become refractory to available treatments and will require additional therapy. However, data are still lacking on how best to sequence regimens in the relapsed/refractory (RR) setting after the failure of early-line lenalidomide, bortezomib, and/or daratumumab, the most commonly used agents in clinical practice today. With the treatment landscape rapidly changing in response to emerging clinical trial data and approvals of several new drugs and additional combinations, it is critically important to focus on patients with RRMM...
March 22, 2023: Blood Cancer Journal
#7
Sæmundur Rögnvaldsson, Thorvardur Jon Love, Sigrun Thorsteinsdottir, Elín Ruth Reed, Jón Þórir Óskarsson, Íris Pétursdóttir, Guðrún Ásta Sigurðardóttir, Brynjar Viðarsson, Páll Torfi Önundarson, Bjarni A Agnarsson, Margrét Sigurðardóttir, Ingunn Þorsteinsdóttir, Ísleifur Ólafsson, Ásdís Rósa Þórðardóttir, Elías Eyþórsson, Ásbjörn Jónsson, Andri S Björnsson, Gunnar Þór Gunnarsson, Runólfur Pálsson, Ólafur Skúli Indriðason, Gauti Kjartan Gíslason, Andri Ólafsson, Guðlaug Katrín Hákonardóttir, Manje Brinkhuis, Sara Lovísa Halldórsdóttir, Tinna Laufey Ásgeirsdóttir, Hlíf Steingrímsdóttir, Ragnar Danielsen, Inga Dröfn Wessman, Petros Kampanis, Malin Hultcrantz, Brian G M Durie, Stephen Harding, Ola Landgren, Sigurður Yngvi Kristinsson
No abstract text is available yet for this article.
March 20, 2023: Blood Cancer Journal
#8
JOURNAL ARTICLE
Borja Puertas, Verónica González-Calle, Eduardo Sobejano-Fuertes, Fernando Escalante, Beatriz Rey-Bua, Irene Padilla, Ramón García-Sanz, Noemi Puig, Norma C Gutiérrez, María-Victoria Mateos
Multiple myeloma (MM) patients with t(11;14) present unique biological features and their prognosis is not well established. We report a retrospective study of 591 MM patients, 17.3% of whom had t(11;14). It was designed to determine the prognostic impact of this abnormality and the effect of novel agents on the response and outcomes. Three groups were established based on their cytogenetics: (1) t(11;14); (2) high-risk chromosomal abnormalities; and (3) standard risk (SR). After 80.1 months (1.2-273.8 months) of follow-up, no differences were observed in overall survival (OS) between the t(11;14) and SR groups (75...
March 20, 2023: Blood Cancer Journal
#9
JOURNAL ARTICLE
Jonathan Carmichael, Frances Seymour, Graham McIlroy, Sarrah Tayabali, Rosie Amerikanou, Sylvia Feyler, Rakesh Popat, Guy Pratt, Christopher Parrish, A John Ashcroft, Graham H Jackson, Gordon Cook
The COVID-19 pandemic has had global healthcare impacts, including high mortality from SARS-CoV-2 infection in cancer patients; individuals with multiple myeloma (MM) are especially susceptible to poor outcomes. However, even for MM patients who avoided severe infection, the ramifications of the pandemic have been considerable. The consequences of necessary socio-geographical behavior adaptation, including prolonged shielding and interruptions in delivery of non-pandemic medical services are yet to be fully understood...
March 15, 2023: Blood Cancer Journal
#10
JOURNAL ARTICLE
Marthe Minderman, Hildo C Lantermans, Leonie J Grüneberg, Saskia A G M Cillessen, Richard J Bende, Carel J M van Noesel, Marie José Kersten, Steven T Pals, Marcel Spaargaren
The paracaspase mucosa-associated lymphoid tissue 1 (MALT1) is a protease and scaffold protein essential in propagating B-cell receptor (BCR) signaling to NF-κB. The deubiquitinating enzyme cylindromatosis (CYLD) is a recently discovered MALT1 target that can negatively regulate NF-κB activation. Here, we show that low expression of CYLD is associated with inferior prognosis of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) patients, and that chronic BCR signaling propagates MALT1-mediated cleavage and, consequently, inactivation and rapid proteasomal degradation of CYLD...
March 15, 2023: Blood Cancer Journal
#11
EDITORIAL
Anushka Walia, Vinay Prasad
No abstract text is available yet for this article.
March 15, 2023: Blood Cancer Journal
#12
LETTER
Mostafa Abdallah, Kristen McCullough, Rimal Ilyas, Kebede H Begna, Aref Al-Kali, Mark R Litzow, William J Hogan, Abhishek Mangaonkar, Hassan Alkhateeb, Mithun V Shah, Michelle A Elliott, James M Foran, Talha Badar, Jeanne M Palmer, Cecilia Arana Yi, Lisa Sproat, Animesh Pardanani, Mrinal M Patnaik, Horatiu Olteanu, Rhett P Ketterling, Ayalew Tefferi, Naseema Gangat
No abstract text is available yet for this article.
March 13, 2023: Blood Cancer Journal
#13
LETTER
Beatrice Z Sim, Anthony Longhitano, Jeremy Er, Simon J Harrison, Monica A Slavin, Benjamin W Teh
No abstract text is available yet for this article.
March 10, 2023: Blood Cancer Journal
#14
LETTER
Philippe Moreau, Ajai Chari, Albert Oriol, Joaquin Martinez-Lopez, Mathias Haenel, Cyrille Touzeau, Sikander Ailawadhi, Britta Besemer, Javier de la Rubia Comos, Cristina Encinas, Maria-Victoria Mateos, Hans Salwender, Paula Rodriguez-Otero, Cyrille Hulin, Lionel Karlin, Anna Sureda Balari, Joan Bargay, Lotfi Benboubker, Laura Rosiñol, Stefano Tarantolo, Howard Terebelo, Shiyi Yang, Jianping Wang, Ivo Nnane, Ming Qi, Michele Kosh, Maria Delioukina, Hartmut Goldschmidt
No abstract text is available yet for this article.
March 7, 2023: Blood Cancer Journal
#15
JOURNAL ARTICLE
Rodrigo Fonseca, Mariano Arribas, Julia E Wiedmeier-Nutor, Yael N Kusne, Miguel González Vélez, Heidi E Kosiorek, Richard Duke J Butterfield, Ilan R Kirsch, Joseph R Mikhael, A Keith Stewart, Craig Reeder, Jeremy Larsen, P Leif Bergsagel, Rafael Fonseca
Minimal residual disease (MRD) assays allow response assessment in patients with multiple myeloma (MM), and negativity is associated with improved survival outcomes. The role of highly sensitive next generation sequencing (NGS) MRD in combination with functional imaging remains to be validated. We performed a retrospective analysis on MM patients who underwent frontline autologous stem cell transplant (ASCT). Patients were evaluated at day 100 post-ASCT with NGS-MRD and positron emission tomography (PET-CT)...
March 6, 2023: Blood Cancer Journal
#16
JOURNAL ARTICLE
Maria Moscvin, Christine Ivy Liacos, Tianzeng Chen, Foteini Theodorakakou, Despina Fotiou, Shahrier Hossain, Sean Rowell, Houry Leblebjian, Eileen Regan, Peter Czarnecki, Filippo Bagnoli, Niccolo' Bolli, Paul Richardson, Helmut G Rennke, Meletios A Dimopoulos, Efstathios Kastritis, Giada Bianchi
Thrombotic microangiopathy (TMA) has been reported to occur in multiple myeloma (MM) patients in association with treatment with carfilzomib, an irreversible proteasome inhibitor (PI). The hallmark of TMA is vascular endothelial damage leading to microangiopathic hemolytic anemia, platelet consumption, fibrin deposition and small-vessel thrombosis with resultant tissue ischemia. The molecular mechanisms underlying carfilzomib-associated TMA are not known. Germline mutations in the complement alternative pathway have been recently shown to portend increased risk for the development of atypical hemolytic uremic syndrome (aHUS) and TMA in the setting of allogeneic stem cell transplant in pediatric patients...
February 27, 2023: Blood Cancer Journal
#17
LETTER
Somayya Noori, Charissa Wijnands, Pieter Langerhorst, Vincent Bonifay, Christoph Stingl, Cyrille Touzeau, Jill Corre, Aurore Perrot, Philippe Moreau, Hélène Caillon, Theo M Luider, Thomas Dejoie, Joannes F M Jacobs, Martijn M van Duijn
No abstract text is available yet for this article.
February 24, 2023: Blood Cancer Journal
#18
LETTER
Kathryn T Maples, Kevin H Hall, Nisha S Joseph, Craig C Hofmeister, Vikas Gupta, Madhav V Dhodapkar, Jonathan L Kaufman, Ajay K Nooka, Sagar Lonial
No abstract text is available yet for this article.
February 20, 2023: Blood Cancer Journal
#19
JOURNAL ARTICLE
Alexander J Ryu, Shaji Kumar, Angela Dispenzieri, Robert A Kyle, S Vincent Rajkumar, Thomas C Kingsley
Monoclonal gammopathy of undetermined significance (MGUS) is a benign hematological condition with the potential to progress to malignant conditions including multiple myeloma and Waldenstrom macroglobulinemia. Medications that modify progression risk have yet to be identified. To investigate, we leveraged machine-learning and electronic health record (EHR) data to screen for drug repurposing candidates. We extracted clinical and laboratory data from a manually curated MGUS database, containing 16,752 MGUS patients diagnosed from January 1, 2000 through December 31, 2021, prospectively maintained at Mayo Clinic...
February 17, 2023: Blood Cancer Journal
#20
JOURNAL ARTICLE
Yuxuan Che, Yang Liu, Yixin Yao, Holly A Hill, Yijing Li, Qingsong Cai, Fangfang Yan, Preetesh Jain, Wei Wang, Lixin Rui, Michael Wang
Constant challenges for the treatment of mantle cell lymphoma (MCL) remain to be recurrent relapses and therapy resistance, especially in patients harboring somatic mutations in the tumor suppressors ATM and TP53, which are accumulated as therapy resistance emerges and the disease progresses, consistent with our OncoPrint results that ATM and TP53 alterations were most frequent in relapsed/refractory (R/R) MCL. We demonstrated that protein arginine methyltransferase-5 (PRMT5) was upregulated in R/R MCL, which predicted a poor prognosis...
February 17, 2023: Blood Cancer Journal
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
